Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of Two Doses of INV-202 in Patients With Diabetic Kidney Disease

NCT05514548 is registered in ClinicalTrials.gov with Inversago Pharma Inc. as lead sponsor.

NCT NCT05514548
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05514548 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of Two Doses of INV-202 in Patients With Diabetic Kidney Disease
Lead sponsor
Inversago Pharma Inc.
Phase
Phase 2
Overall status
Completed
Start date
October 19, 2022
Completion date
September 3, 2024
Enrollment
265 (actual)
Sites
72

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic kidney disease